Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.

Detailed price information for Rallybio Corporaton (RLYB-Q) from The Globe and Mail including charting and trades.

While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.

Former Google CEO Eric Schmidt warns that Artificial Superintelligence (ASI), surpassing human intelligence, is imminent. He ...

Morgan Stanley initiated coverage on three AI-integrated biotechnology firms, Absci, Schrodinger (NASDAQ:SDGR), and Recursion Pharmaceuticals, flagging divergent business models and upcoming catalysts ...

So, you’re wondering what the deal is with programming languages for artificial intelligence, especially as we head ...

Handpicked titles for beginner to senior-level software rolesCovers coding, system design, clean code, and real-world problem ...

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- Several experts are seeing that value of AI's total overhaul ...